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Plasmodium vivax infections often recur due to relapse of hypnozoites from the liver. In malaria-endemic areas,
tools to distinguish relapse from reinfection are needed. We applied amplicon deep sequencing to P. vivax iso-
lates from 78 Cambodian volunteers, nearly one-third of whom suffered recurrence at a median of 68 days. Deep
sequencing at a highly variable region of the P. vivax merozoite surface protein 1 gene revealed impressive di-
versity—generating 67 unique haplotypes and detecting on average 3.6 cocirculating parasite clones within in-
dividuals, compared to 2.1 clones detected by a combination of 3 microsatellite markers. This diversity enabled a
scheme to classify over half of recurrences as probable relapses based on the low probability of reinfection by
multiple recurring variants. In areas of high P. vivax diversity, targeted deep sequencing can help detect genetic
signatures of relapse, key to evaluating antivivax interventions and achieving a better understanding of relapse-
reinfection epidemiology.
Keywords. amplicon sequencing; deep sequencing; genetic diversity; hypnozoite; malaria; microsatellite;
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In recent years, there has been an increased apprecia-
tion that global malaria elimination efforts cannot suc-
ceed without a better understanding of Plasmodium vivax,
the leading cause of malaria outside Africa [1–3]. In par-
ticular, P. vivax’s ability to cause periodic relapse poses
a major barrier to malaria elimination, because hypno-
zoites, the parasite stages in the liver that reactivate to
cause relapse, are not killed by traditional blood-stage
drugs [4, 5].
In Southeast Asia, P. vivax relapses are common and
frequent: up to two-thirds of individuals not treated
with antirelapse therapy suffer 1 or more relapses, ap-
proximately 3–4 weeks after plasma levels of antimalar-
ials wane [6–11].However, because individuals can also
become reinfected, it is difficult to determine the true
relapse rate and to distinguish when treatment failures
are due to relapse. Molecular genotyping aimed at distin-
guishing relapses from reinfections has been confounded
by the frequent finding of genetically different parasites
at relapse, even in the setting of known relapse [12–15].
Thus, tools to assess interventions targeting P. vivax in
clinical studies are missing.
We and others have previously shown that P. vivax
populations in Thailand and Cambodia exhibit great
genetic diversity despite relatively low-level transmis-
sion: many alleles circulate on a population level, and
individuals commonly harbor multiple genetic variants
at once [16–18].With this diversity in mind, we applied
targeted deep sequencing to a malaria cohort in Cam-
bodia in which one-third of individuals suffered recur-
rent P. vivax infections. We hypothesized that the
within-host diversity unveiled by deep sequencing at a
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highly polymorphic molecular marker would expose genotypic
patterns suggestive of relapse. We found that enhanced detection
of minority variants revealed patterns of variant overlap between
initial and recurrent parasite isolates within individuals. This
finding, combined with population-based characterization of
haplotypes, provide a statistical framework for determining the
probability of reinfection and relapse. Our findings shed light
on the nature of P. vivax hypnozoite activation and represent im-
portant steps toward identifying genotypic signatures of relapse.
MATERIALS AND METHODS
Study Population
We studied parasites collected from 78 P. vivax–infected adults,
aged 18 to 49, enrolled in a malaria cohort and treatment study
conducted from September 2010 to March 2011 in Oddar
Meanchay province in northern Cambodia [19]. Of the 220 co-
hort volunteers, most were military personnel with frequent
travel to forested areas. The first 80 subjects who developed ma-
laria (either falciparum or vivax) were treated with dihydroarte-
misinin-piperaquine, after which vivax patients were treated
with chloroquine per national Cambodian treatment guidelines.
Subjects were followed for recurrence with weekly blood smears
for 6 weeks, then by clinical symptoms thereafter with a month-
ly blood smear. Those with P. vivax were treated with prima-
quine to clear liver-stage hypnozoites at the conclusion of
their participation in the cohort study, which ranged from 2
to 6 months’ duration. Ethical approval for the study was grant-
ed by the institutional review boards of the University of North
Carolina, Walter Reed Army Institute of Research, and the Na-
tional Ethics Committee for Health Research in Cambodia.
Amplicon Deep Sequencing of pvmsp1
DNA from filter paper blood spots was extracted using the In-
vitrogen Pro 96 Genomic DNA kit (Invitrogen, Carlsbad,
California). A 117–base pair (bp) variable portion of the 33-
kDa subunit of the 42-kDa region of pvmsp1 (Figure 1A) was
Figure 1. Ultradeep sequencing of pvmsp1. A, The target amplicon contained a 117-bp variable region of the 42-kDa fragment of pvmsp1. B, DNA
alignment of all 67 unique pvsmp1 variants detected in the 108 isolates from 78 individuals. Each concentric ring represents a unique sequence. Nucleotides
are represented by different colors (adenine, red; thymine, blue; cytosine, green; and guanine, yellow). C, Frequency of unique pvmsp1 haplotypes within the
study population (out of 108 isolates). Only haplotypes that appeared in more than 1 isolate are shown. The red portions of the columns represent the
proportion that occurred as a minority variant (existing at 0.5%–20% frequency within the individual isolate). D, Multiplicity of infection among initial (blue)
and recurrent (green) isolates. Abbreviation: bp, base pair.
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chosen for deep sequencing based on previous work showing
great nucleotide diversity across this region [20]. Amplicons
were generated using nested polymerase chain reaction (PCR)
using the primers and conditions listed in the Supplementary
Methods. Forward primers used in the second round were mod-
ified for Ion Torrent sequencing by inclusion of a multiplex
identifier (MID) sequence. Each sample was amplified in dupli-
cate, using unique MIDs. If amplification failed, the cycle num-
ber in both rounds was increased to 35 cycles. This was
necessary in approximately one-quarter of the samples. Ampli-
cons were cleaned and normalized to 1–2 ng/µL concentration
using the SequalPrep Normalization Plate Kit (Life Technolo-
gies, Carlsbad, California), then pooled and sequenced on the
Ion Torrent platform from Life Technologies.
Haplotype Determination From Deep Sequencing
Haplotypes of pvmsp1 variants were determined by an in-house
bioinformatics pipeline that uses a clustering method to con-
struct the most likely haplotypes within a patient while remov-
ing false haplotypes due to PCR or sequencing error (http://
baileylab.umassmed.edu/seekdeep). In brief, raw sequence
reads were separated on the basis of MIDs from the pooled
data into amplicon-specific data, then filtered on read length,
overall quality scores, and presence of primer sequences. Ampli-
con reads were trimmed of MIDs, tags, and primers and orga-
nized into unique clusters based on their sequence. Then, for
each sample, sequence clusters differing only by indels of 1
and 2 bases or sequences harboring low-quality mismatches
or low k-mer frequency errors (k-mer occurring less than
0.2%) were collapsed together. Low quality was defined as either
a mismatching base Q < 20 or any Q < 15 within an 11 bp re-
gion centered on the mismatch, as has been applied previously
to rigorous single-nucleotide polymorphism discovery from
shotgun data [21]. Next, potential PCR chimeras within patients
were identified and removed based on the presence of both po-
tential parental frequencies existing at higher frequencies with
the patient. Finally, for each patient, haplotype clusters that
were present in 2 independent duplicate PCR samples at
≥0.5% frequency were counted as unique variants. In this
way, consensus haplotype determination was performed across
the combined haplotypes from all individuals. Final haplotypes
for analysis were each assigned a unique population identifier
(CAM.00–CAM.66).
Microsatellite Genotyping
A subset of 65 samples were also genotyped at 3 microsatellite
markers using previously published primers: PvMS7 and
PvMS10 on chromosomes 2 and 5 [22], respectively, and
MS10 on chromosome 13 (referred to here as MS10.13) [23].
PvMS7 and MS10.13 have been recommended as microsatellite
markers of highest priority based on their balanced representa-
tion of diversity and frequent use [24], and MS10.13 was
previously shown to exhibit high diversity in Cambodia [17].
PCR was performed using the same conditions for all 3 markers
(Supplementary Text), except that hemi-nested PCR was used
in samples where MS10.13 had poor amplification. Fragments
were sized on a 3730 × L DNA Analyzer with results analyzed
using Gene Mapper 4.1 software (Applied Biosystems). Peaks
above a threshold of 100 units of relative fluorescent intensity
and distinct above background noise were considered true am-
plification products, while peaks that were less than one-third
the intensity of the strongest peak or visually appeared to be
stutter peaks were excluded [25]. Alleles were grouped into
bins of 3 bp for PvMS7 and MS10.13 and 4 bp for PvMS10
based on the expected repeat size for each microsatellite.
Data Analysis
The final haplotypes were stored and analyzed in Microsoft
Excel 2007. Multiplicity of infection (MOI) was defined as the
number of unique pvmsp1 haplotypes detected per patient iso-
late, or in the case of the microsatellite sequencing data, the
greatest number of alleles detected in any of the 3 markers. Ge-
netic diversity for each genotyping method was estimated by
calculating the virtual heterozygosity (HE) [25]. Agreement be-
tween genotyping methods was assessed using the κ coefficient.
DNA alignments and figures were generated using MegAlign
and GenVison software (DNAStar, Madison, Wisconsin). The
median-joining network was created using DNA Alignment
v1.2.1.1 and Network v4.6.1.2 (Fluxus Technology, Suffolk,
England). Statistical analysis was done using STATA v.12.0
(STATA Corp, College Station, Texas).
RESULTS
P. vivax Genetic Diversity by Amplicon Deep Sequencing
DNA from all 108 P. vivax samples from 78 Cambodian volun-
teers were successfully amplified in duplicate at a 117-bp-
variable region of pvmsp1 and subjected to ultra-deep sequenc-
ing using the Ion Torrent platform. After quality filtering, a me-
dian of 3237× coverage was achieved per patient sample, and
2 873 657 (97%) of the high-quality reads clustered contributed
to utilized haplotypes. The deep coverage enabled detection of
variants present at as low as 0.5% within-host frequency, as this
threshold translated into an average of approximately 16 se-
quence reads. In total, 67 unique pvmsp1 haplotypes were de-
tected across the 108 isolates (Figure 1B, Supplementary
Figure 1). Overall, these haplotypes displayed 59 variable sites,
with the majority displaying nonsynonymous substitutions.
Nine common haplotypes appeared in at least 10% of individ-
uals (Figure 1C), while two-thirds (46/67) of haplotypes ap-
peared in only 1 isolate. Virtual heterozygosity at this locus
was HE = 0.95, reflecting an average 95% probability that 2 par-
asite clones taken at random from the population will display
different pvmsp1 haplotypes.
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Multiplicity of Infection and Detection of Minority Variants
In-host genetic diversity revealed by pvmsp1 deep sequencing was
also high. Most initial P. vivax episodes (90%) were composed of
polyclonal infections, with an average of 3.6 cocirculating vari-
ants, while as many as 10 variants were identified in 1 isolate
(Figure 1D). The in-host frequency of each variant, calculated
by its proportion of reads within the total reads per individual,
demonstrated good concordance between duplicate PCRs done
on each isolate using a summed distance metric to quantify
noise [26] (Supplementary Figure 2). Minority variants were de-
fined as those existing at <20% in-host frequency [27]. Sixty per-
cent of the 67 identified haplotypes were detected only as
minority variants. Some of these minority variant formed part
of the mutational path between the more common variants, as
depicted in a median joining network based on sequence related-
ness, adding support that they are true haplotypes that are not a
result of PCR or sequencing error (Figure 2).
Comparison of Amplicon Deep Sequencing to Microsatellite
Genotyping
The subset of 65 isolates also genotyped at 3 P. vivax microsat-
ellite markers similarly revealed high genetic diversity but on
average, less genetic complexity within isolates, compared to
deep sequencing (Table 1). When results from 3 microsatellite
markers were combined, 72% of isolates were polyclonal, com-
pared to 92% by sequencing, and contained an average of 2.1
variants, compared to average of 3.8 variants detected by deep
sequencing (P < .001). In a small fraction of isolates (6/65), the
combined microsatellite markers revealed a higher MOI than
deep sequencing, but there was only 1 case in which a polyclon-
al infection identified by microsatellite typing was “missed” by
deep sequencing at pvmsp1. Overall, the agreement between the
2 genotyping methods for detecting polyclonal infections was
fair (κ coefficient = 0.26 [95% confidence interval, .02–.50]).
Genotypic Patterns of P. vivax Recurrences
Eight subjects developed P. vivax after treatment for P. falcipa-
rum. Of the other 69 subjects who developed P. vivax and were
subsequently followed for a median of 115 days, 22 individuals,
or approximately one-third of the cohort, developed recurrent
P. vivax infection [15]: 16 subjects suffered 1 recurrence, 5 suf-
fered 2 recurrences, and 1 subject suffered 3 recurrences. There-
fore, a total of 29 P. vivax recurrences, occurring a median of 68
days (range, 2.5–18 weeks) after treatment with artemisinin-
based combination therapy, were available for genotypic
analysis. Recurrences were as likely as initial infections to be
polyclonal. There was also no difference in the allelic diversity
seen in recurrent versus initial infections. Variant CAM.01 ap-
peared to arise more commonly in recurrent infections, while
CAM.04 was seen more commonly in initial infections, but nei-
ther of these observations was significant when accounting for
multiple comparisons (Figure 2).
Figure 2. Median joining network of pvmsp1 haplotypes showing all variants detected. Larger nodes depict the common variants. The proportion of
samples with the designated haplotype detected in initial and recurrent infections are depicted in white and black, respectively. Nodes representing se-
quences on the mutational pathway between haplotypes that were not detected are unlabeled. Spatial organization and distance between nodes is
arbitrary.
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The relatedness of recurrent pairs was classified according to
the degree of overlap between variants found in the recurrent iso-
late versus the preceding episode (ie, 10R compared to 10, 10RR
compared to 10R) (Figure 3). Among the 29 recurrent pairs, ap-
proximately one-third or 11/29 were homologous by deep se-
quencing, exhibiting the same dominant or codominant
pvmsp1 haplotypes (Figure 3A and 3B). Of the remaining heter-
ologous (nonhomologous) pairs, over half (10/18) appeared re-
lated, displaying both shared (recurring) and novel pvmsp1
variants at recurrence (Figure 3C and 3D). The rest (8/18) dis-
played completely different genotypes made up of novel variants
at recurrence not seen in the preceding infection (Figure 3E ).
Table 1. Comparison of MOI and Diversity by Ion Torrent Amplicon Deep Sequencing Versus Microsatellite Genotyping (N = 65 Samples)
Deep Sequencing
Microsatellite Genotyping
Pvmsp1 PvMS7 PvMS10 MS10.13 MS Markers Combined
Median MOI 3 1 1 2 2
Mean MOI 3.8 1.5 1.4 1.8 2.1
Max MOI 10 3 4 5 5
No. polyclonal 60 27 17 33 47
% polyclonal 92% 42% 26% 51% 72%
No. alleles 52 19 15 20 NA
Virtual heterozygosity (HE) 0.94 0.92 0.84 0.94 NA
Abbreviations: MOI, multiplicity of infection; MS, microsatellite; NA, not applicable.
Figure 3. Representative genotypes of recurrent pairs categorized into homologous or heterologous pairs (A) based on overlap of pvmsp1 variants in the
recurrent and preceding infection. Unique haplotypes are represented by specific colors across all samples. B, Homologous pairs were defined as having the
same dominant or codominant haplotype at recurrence as seen in the preceding episode. C, In pairs exhibiting minority variant expansion, a minority
parasite population existing at <20% in-host frequency in the initial infection reappeared as the dominant variant at recurrence. D, At least 1 shared variant
defined our third category, while one-third of heterologous pairs shared no overlap at all (E ). Pairs identified as probable relapses based on statistical testing
are denoted by an asterisk. A pair that was “indeterminate” by statistical testing but judged as likely relapse based on microsatellite results are denoted by
double asterisks. The genotypes of all 29 pairs are depicted in Supplementary Figure 3 (21 depicted here).
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Microsatellite genotyping revealed strikingly different results: of
the 21 pairs that were homologous or appeared related by deep
sequencing, different alleles were detected at recurrence in at
least 1 of the 3 microsatellite markers in all but 2 pairs.
Minority Variant Expansion
In one-third of the heterologous recurrences (6/18), the recur-
rence genotype displayed a pattern of minority variant expan-
sion, in which a variant existing at <20% in-host frequency in
the initial infection reappeared as the dominant variant at recur-
rence (Figure 3B). This type of pattern is illustrated in patient 81,
who in successive recurrences, each 31–35 days after the previous
episode, harbored an increasing fraction of the CAM.00 variant
until it was the dominant clone in the third recurrence (Fig-
ure 4A). This 20-year-old patient denied ever having malaria in
the past and was also pvmsp1 antibody–negative upon enroll-
ment (unpublished data), supporting the conclusion that his ini-
tial P. vivax episode was a primary mosquito-inoculated infection
followed by 3 hypnozoite-induced relapses. Microsatellites geno-
typing in this patient showed different alleles in at least 1 marker
at each transition. However, when minor peaks (distinct from
background fluorescence but less than one-third the intensity
of the strongest peak) were included for comparison, recurring
alleles at each marker also support the impression that the patient
suffered multiple relapses rather than new infections (Figure 4B).
Classification of Recurrences as Relapses
To determine whether recurrence pairs with shared variants
likely represent relapses, we employed a method used previously
to distinguish P. falciparum recrudescence and reinfection: we
calculated the probability that variants would recur in the
same person by chance given their overall population preva-
lence [28]. This probability is meant to reflect the likelihood
that the recurrence genotype represents a new mosquito-
inoculated infection. Thus, for the recurrent patient with x var-
iants and sharing a single variant of prevalence y, the binomial
probability [29] that this variant is found by chance in a recur-
rent infection is calculated as 1−(1−y)x.
The probabilities of reinfection by the same variants for the 11
homologous pairs and 10 related pairs by deep sequencing are
shown in Table 2. In recurrences where there were multiple shared
variants, the combined probability that all shared variants would
appear in a reinfection is calculated as the product of the individ-
ual probabilities. To classify recurrences as probable relapses aris-
ing from hypnozoites within the patient, we employed a cutoff of
10%, where if the probability of reinfection by the shared variant
(s) is≤0.10, the recurrence is classified as a relapse, and otherwise,
“indeterminate.” Among the 21 homologous and related pairs, 5
had reinfection probabilities of 10%–20%, placing them in the in-
determinate category. We evaluated the microsatellite data in the
indeterminate pairs and found that 2 (patients 123 and 151) dem-
onstrated similar alleles at all 3 microsatellite markers tested, mak-
ing it unlikely that the recurrent infection was an unrelated new
infection. These 2 pairs were thus reclassified as probable relapses.
Overall, based primarily on deep sequencing data, but using
microsatellites to reclassify 2 indeterminate pairs, we concluded
that over half (18/29) of the recurrent infections were caused by
relapse (Supplementary Figure 3). There was no difference in
time to recurrence in those recurrences classified as relapse ver-
sus not (median days to recurrence, 68 [range, 31–126] vs 82
[range, 17–115], respectively; P = .8).
DISCUSSION
The lack of genotyping tools to distinguish P. vivax relapses
from reinfections in endemic settings has hindered efforts to
Figure 4. Pictoral representation of pvmsp1 haplotypes and microsatellite alleles MS7, MS10, and MS10.13 found in patient 81 through 4 consecutive P.
vivax parasitemic episodes. In Panel A, pie slices reflect the proportion of sequencing reads assigned to each pvmsp1 haplotype variant within each episode
(CAM.00 in red, CAM.01 in blue, CAM.51 in yellow). In Panel B, microsatellite alleles for PvMS7, PvMS10, and MS10.13 are depicted as different colored
triangles, squares, and rectangles, respectively, within each tripart segment. Alleles that appeared only as minor peaks (less than one-third height of the
dominant allele peak) are depicted as hollow shapes.
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81 - -> 81R 35 2 CAM.01 0.061 0.118 0.024 Relapse
CAM.00 0.105 0.200
81R - -> 81RR 34 2 CAM.01 0.061 0.118 0.024 Relapse
CAM.00 0.105 0.200
81RR - -> 81RRR 31 3 CAM.00 0.105 0.284 0.049 Relapse
CAM.01 0.061 0.172
82 - -> 82R 56 4 CAM.03 0.046 0.172 0.062 Relapse
CAM.00 0.105 0.360




96 - -> 96R 71 2 CAM.00 0.105 0.200 0.200 Indeterminate
123 - -> 123R 68 2 CAM.00 0.105 0.199 0.199 Indeterminate
126 - -> 126R 85 3 CAM.07 0.035 0.100 0.017 Relapse
CAM.01 0.061 0.172
130 - -> 130R 68 3 CAM.12 0.013 0.284 0.002 Relapse
CAM.04 0.049 0.141
CAM.00 0.105 0.039
151 - -> 151R 126 4 CAM.08 0.026 0.101 0.101 Indeterminate
152 - -> 152R 94 4 CAM.00 0.105 0.360 0.080 Relapse
CAM.01 0.061 0.223
Heterologous pairs with shared and novel variants
Minority variant expansion
10 - -> 10R 84 3 CAM.00 0.105 0.284 0.010 Relapse
CAM.11 0.012 0.034
68 - -> 68R 99 1 CAM.10 0.013 0.013 0.013 Relapse




87 - -> 87R 81 4 CAM.00 0.105 0.360 0.036 Relapse
CAM.08 0.026 0.101
112 - -> 112R 67 3 CAM.00 0.105 0.284 0.009 Relapse
CAM.02 0.066 0.185
CAM.01 0.061 0.172
130R - -> 130RR 43 2 CAM.00 0.105 0.199 0.199 Indeterminate
Shared variant(s)
36 - -> 36R 99 4 CAM.07 0.035 0.131 0.007 Relapse
CAM.02 0.066 0.239
CAM.01 0.061 0.223
80 - -> 80R 56 10 CAM.00 0.105 0.672 0.050 Relapse
CAM.08 0.026 0.232
CAM.05 0.038 0.321
125 - -> 125R 82 9 CAM.02 0.066 0.459 0.459 Indeterminate
154 - -> 154R 64 3 CAM.06 0.035 0.100 0.100 Relapse
a Listed in descending order of in-host frequency; dominant clone is bolded.
b Calculated as 1-(1-y)x for the recurrent patient with x variants and sharing a single variant of prevalence y.
c Calculated as the product of the reinfection probabilities for all shared variants.
d Recurrent genotypes with ≤10% chance of reinfection with the observed shared variants are classified as relapse.
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evaluate antirelapse drugs like primaquine, and to evaluate the
epidemiologic burden of infection due to relapses. While mul-
tiple studies have previously aimed to characterize relapses
using highly discriminatory molecular markers, they invariably
reach the conclusion that relapses frequently display novel ge-
notypes compared to those detected initially, making it impos-
sible to distinguish them from novel genotypes arising from
new mosquito bites [12–15, 30, 31].
The appearance of novel genotypes even among known relaps-
es has at least 3 plausible contributing explanations. First, persons
living in endemic areas who have been exposed to multiple vivax
infections over a lifetime likely harbor a diverse collection of hyp-
nozoites within their liver [9, 32]. Reactivation of latent hypno-
zoites from this library of past infections can lead to emergence
of variants not present in the most recently observed episode.
Second, as demonstrated by the examples of minority variant ex-
pansion found within our cohort by deep sequencing, apparently
novel clones at relapse may in fact have existed originally as mi-
nority variants below the limit of detection. In our patient with 3
recurrences, deep sequencing suggested successive relapses with a
minority clone increasing in proportion at each relapse. However,
the microsatellite picture was more confusing—only by examin-
ing minor alleles not originally counted could the same variants
be appreciated through successive episodes, highlighting the loss
of useful information when minority variants are missed (Fig-
ure 4). Finally, infections inoculated by a single mosquito bite
have been shown to contain different but closely related geno-
types, representing sporozoites that arose from meiotic recombi-
nation within the mosquito [33–36]. The detectability of these
“sibling” genotypes likely varies at different samplings.
To address the above, we propose a relapse classification
scheme that assumes that consecutive vivax malaria episodes
arising from relapse will often contain heterologous hypno-
zoites, but should also be composed of recurring variants aris-
ing from the same latent hypnozoite reservoir within an
individual. Our previous work using heteroduplex tracking as-
says suggested that variant overlap is common among relapses
when minority variants are detected [16, 37, 38]. Similarly, in a
comprehensive microsatellite genotyping study of Brazilians
who developed relapse without re-exposure to a malaria-
endemic setting, more homology was noted between consecu-
tive relapse episodes when nondominant microsatellite alleles
were taken into consideration [15].
Here, we build on these previous findings by using amplicon
deep sequencing to highlight patterns of multivariant overlap
that are unlikely to happen by chance. To detect this overlap,
we targeted pvmsp1, an antigenic marker with great nucleotide
diversity, to sensitively detect minority parasite clones. By eval-
uating pvmsp1 variant overlap, we identified over half of recur-
rence pairs as representing probable relapse. This is biologically
plausible in a region where transmission is relatively low (on av-
erage, persons are exposed to <1 infected mosquito bite per
year) but where local vivax strains are known to cause frequent
relapse [9].
One could argue that microsatellites were found to be more
discriminatory in our cohort and are also neutral to immune
selection, and that these advantages outweigh the problem of
less sensitive and specific detection of minority alleles. However,
the very hypervariability of microsatellite repeats may render
them less useful for comparing individual genotypes longitudi-
nally within persons to look for recurring variants. We propose
that different microsatellite alleles found at relapse may often
represent closely related sibling parasite subpopulations that
arose from the same mosquito inoculation [33]. Genotyping
may variably detect microsatellite subclones that are different
sizes, but nonetheless reactivate on a clonal basis and demon-
strate the same antigenic clone (ie, pvmsp1). In other words,
if microsatellite siblings are branches of the same tree, differen-
tial hypnozoite reactivation likely occurs at the tree level within
a forest, instead of at the branch level. Such nuances can likely
only be explored with whole-genome analysis of single clones
within polyclonal relapsing infections [35, 39]. Direct compari-
son of such data with microsatellite and deep sequencing results
would help clarify what level of clone differentiation is impor-
tant for describing relapse phenotypes.
The major obvious limitation to our analyses is our reliance
on samples from an endemic cohort, and therefore uncertainty
arises regarding which of the recurrent infections were actually
caused by relapse arising from hypnozoites, as opposed to rein-
fection from a mosquito bite or recrudescence of blood-stage
parasites due to drug resistance. We feel that recurrence due
to recrudescence was unlikely, as all subjects were treated with
directly observed artemisinin-based combination therapy
known to be highly effective against P. vivax and cleared their
parasites rapidly [19]. On the other hand, reinfections from
mosquito bites likely did occur. However, in an area of relatively
low transmission, we expect that the majority of recurrences
were due to relapse.
The lack of a gold standard to determine the source of recur-
rences is a great challenge to vivax genotyping studies in endemic
areas. Our strategy of using local population diversity as a context
for determining when recurring variants were not likely to occur
by chance can be applied to settings where a significant amount
of genetic diversity exists. It will underestimate the proportion of
relapses, as a monoclonal relapse of a variant that may have been
missed originally based on sampling variability, or because it
arose from a historical infection, would not be classified as a
probable relapse [13, 40]. However, the scheme can be refined
based on a greater insight into the detectability of variants over
time, the use of more than 1 sequenced marker, and a greater un-
derstanding of what level of variant differentiation correlates with
relapse. While the outcomes of individual recurrences cannot be
distinguished with absolute confidence, our method provides a
framework for estimating the proportion of recurrences likely
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due to relapse. Otherwise, complicated design strategies are need-
ed for the same purpose [41].
Future studies should employ deep sequencing at multiple
loci, continue to explore how to integrate results from microsat-
ellite markers, and apply these and whole-genome-based anal-
yses to isolates collected in antirelapse trials where exposure is
limited and relapse outcomes are more definitively known
[31, 42, 43]. Ultimately, well-characterized relapsing parasites
collected in field studies could be used in genome-wide associ-
ation studies to understand any genetic determinants of relapse.
Such an understanding would accelerate the development of
effective antirelapse therapies and inform strategies that are
needed to successfully eliminate vivax malaria. Our study, by
characterizing genetic signatures of relapse, represents a first
step toward this important goal.
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